Patient-specific FEV1 reproducibility limits to more accurately track disease progression

S. Stanojevic (Toronto, Canada), N. Filipow (Toronto, Canada), F. Ratjen (Toronto, Canada)

Source: International Congress 2019 – Innovative ways to diagnose and monitor children with lung diseases and sleep-disordered breathing
Disease area: Paediatric lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Stanojevic (Toronto, Canada), N. Filipow (Toronto, Canada), F. Ratjen (Toronto, Canada). Patient-specific FEV1 reproducibility limits to more accurately track disease progression. 1595

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
PRM metrics predict COPD progression
Source: International Congress 2018 – Imaging biomarkers and quantitative imaging
Year: 2018

Duration and frequency of spirometry needed to accurately reflect longitudinal change of FEV1 in COPD
Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases
Year: 2021


The interpretation and discriminatory power of bronchodilator measurements: the influence of baseline lung function and disease type
Source: Eur Respir J 2003; 22: Suppl. 45, 276s
Year: 2003

Which markers other than FEV1 reflect disease progression in COPD?
Source: Eur Respir J 2004; 24: Suppl. 48, 45s
Year: 2004

Is residual volume reversibility a better marker than FEV1 reversibility in diagnosing reversible airway disease  in asthma?
Source: International Congress 2017 – Monitoring novel biomarkers in asthma
Year: 2017



Exploring the clinical utility of measuring reversibility in mid expiratory flow and its relationship with FEV1 reversibility in patients with asthma.
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017

The use of forced oscillation technique (FOT) in assessment and stratification of disease severity in elderly COPD patients
Source: Annual Congress 2011 - Monitoring with lung function tests in airway diseases
Year: 2011


Absolute values of the 6 minute walk distance are equally good to predict disease severity in pulmonary hypertension as percent predicted formulas
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009

Does rapid decline predict poor prognosis?
Source: Annual Congress 2007 - Rapid decline in lung function and its consequences
Year: 2007


COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging
Source: Eur Respir J, 52 (5) 1801570; 10.1183/13993003.01570-2018
Year: 2018



Correlation of various parameters with FEV1 in the assessment of asthma severity
Source: Eur Respir J 2001; 18: Suppl. 33, 51s
Year: 2001

Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS
Source: Eur Respir J, 54 (4) 1802214; 10.1183/13993003.02214-2018
Year: 2019



The ratio of inspiratory ΣRrs to expiratory ΣRrs measured by forced oscillation technique correlates with the parameters reflecting narrowing of small airway measured by spirometry in patients with mild to moderate COPD
Source: Annual Congress 2013 –New issues in lung function testing
Year: 2013

Inter-laboratory variability in the measurement of lung function - contribution of volume calibration errors
Source: Eur Respir J 2004; 24: Suppl. 48, 183s
Year: 2004

Sensitive automated airway-artery method to monitor progression of CF airway disease
Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis
Year: 2021



Utility of impulse oscillometry in prediction of annual decline of pulmonary function in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 59s
Year: 2004

FEV1/FEV6 and FEV6: sensitivity and specificity in detecting obstructive and restrictive disease of older patients
Source: Annual Congress 2008 - Quality spirometry: the only spirometry!
Year: 2008


FEV6: a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004

How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …?
Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets?
Year: 2019


Reproducibility of reversibility in airflow limitation over a year in clinically stable COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 62s
Year: 2005